Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluvoxamine and alcoholism.

R Thomas1

  • 1Whitchurch Hospital, Cardiff, UK.

International Clinical Psychopharmacology
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptake inhibitors, like fluvoxamine, show promise in reducing alcohol consumption and cravings. Further research is needed, particularly in patients with alcohol dependence syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing pneumococcal disease.

Canadian family physician Medecin de famille canadien·1998
Same author

1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997.

The Journal of urology·1998
Same author

Facial paralysis after a road traffic accident.

Journal of the Royal Society of Medicine·1998
Same author

Functional burst imaging.

Magnetic resonance in medicine·1998
Same author

Retroperitoneal and pelvic extraperitoneal laparoscopy: an international perspective.

Urology·1998
Same author

The role of artificial drainage devices in glaucoma surgery.

Indian journal of ophthalmology·1998
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Medicine

Background:

  • Pharmacological manipulation of alcohol intake is a growing area of research.
  • Serotonin reuptake inhibitors (SSRIs) have demonstrated efficacy in reducing alcohol consumption in animal models.
  • Preliminary clinical studies suggest SSRIs may help reduce alcohol intake in early-stage problem drinkers.

Purpose of the Study:

  • To explore the potential of SSRIs, specifically fluvoxamine, in managing alcohol consumption and alcohol-seeking behavior.
  • To investigate the anti-craving effects of serotonin enhancement induced by SSRIs.
  • To present findings from an ongoing study involving fluvoxamine in patients with alcohol dependence syndrome.

Main Methods:

  • Review of animal model studies demonstrating SSRI-induced reduction in alcohol consumption.

Related Experiment Videos

  • Analysis of clinical studies involving SSRIs and early-stage problem drinkers.
  • Description of an ongoing clinical trial with fluvoxamine for alcohol dependence.

    • Main Results:

    • Consistent reduction in alcohol consumption observed in alcohol-preferring rat strains treated with SSRIs.
    • Significant reduction in alcohol intake reported in a group of early-stage problem drinkers using SSRIs.
    • Hypothesized mechanism involves serotonin enhancement reducing alcohol's positive reinforcement properties, leading to anti-craving effects.

    Conclusions:

    • SSRIs, particularly fluvoxamine, show potential as pharmacological treatments for alcohol use disorders.
    • Serotonin enhancement is a likely mechanism for reducing alcohol's rewarding effects and cravings.
    • Replication of these findings, especially in patients meeting criteria for alcohol dependence syndrome, is crucial.